What are the clinical findings of the Bettencourt et al study related to the efficacy of brain natriuretic peptide (BNP) assays?

Updated: Jan 08, 2018
  • Author: Donald Schreiber, MD, CM; Chief Editor: Erik D Schraga, MD  more...
  • Print
Answer

Answer

In this study, change in NT-proBNP level was the strongest predictor of death and/or hospital readmission in hospitalized patients with CHF.

In the report, Portuguese investigators evaluated 182 hospitalized patients with CHF who were followed up for 6 months for a primary endpoint defined as death or hospital readmission for CHF. [54] Levels of NT-proBNP were measured on admission and again at hospital discharge. Patients were stratified as those whose NT-proBNP levels decreased 30% or more between admission and discharge, those with any change less than 30%, and those with an increase of 30% or greater.

At 6 months, 43% of patients died or were readmitted with an exacerbation of CHF. As stated, the change in NT-proBNP level was the strongest predictor of death and/or hospital readmission. However, therapy for CHF was not controlled and was left to the discretion of the attending physician.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!